Tourmaline Bio, Inc.
TRML · NASDAQ
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Market Cap | $411,822 | $390,775 | $523,143 | $662,470 |
| - Cash | $31,423 | $35,330 | $30,506 | $35,008 |
| + Debt | $145 | $196 | $244 | $290 |
| Enterprise Value | $380,544 | $355,641 | $492,881 | $627,752 |
| Revenue | $0 | $0 | $40 | $0 |
| % Growth | – | -100% | – | – |
| Gross Profit | $0 | -$12 | $20 | -$10 |
| % Margin | – | – | 50% | – |
| EBITDA | -$25,974 | -$22,958 | -$22,226 | -$24,428 |
| % Margin | – | – | -55,565% | – |
| Net Income | -$23,092 | -$22,970 | -$22,235 | -$20,177 |
| % Margin | – | – | -55,587.5% | – |
| EPS Diluted | -0.9 | -0.89 | -0.86 | -0.78 |
| % Growth | -1.1% | -3.5% | -10.3% | – |
| Operating Cash Flow | -$20,264 | -$21,679 | -$20,889 | -$23,444 |
| Capital Expenditures | -$7 | -$9 | -$9 | $0 |
| Free Cash Flow | -$20,271 | -$21,688 | -$20,898 | -$23,444 |